{"id":"f2695","safety":{"commonSideEffects":[{"rate":null,"effect":"Hyperphosphatemia"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Stomatitis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"F2695 targets FGFR pathways that are frequently dysregulated in various solid tumors, leading to uncontrolled cell proliferation. By inhibiting FGFR kinase activity, the drug suppresses tumor cell growth and survival in FGFR-dependent malignancies. This mechanism is particularly relevant in cancers with FGFR gene amplifications, fusions, or mutations.","oneSentence":"F2695 is a selective inhibitor of fibroblast growth factor receptor (FGFR) signaling that blocks aberrant growth signals in cancer cells.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:12:14.152Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced or metastatic solid tumors with FGFR alterations"}]},"trialDetails":[{"nctId":"NCT01085812","phase":"PHASE3","title":"Relapse-Prevention Study With Levomilnacipran ER (F2695 SR) in Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2010-03","conditions":"Depression, Major Depressive Disorder","enrollment":734},{"nctId":"NCT02266966","phase":"PHASE1","title":"Effect of F2695 on Brain Activity Measured by Functional Magnetic Resonance Imaging","status":"COMPLETED","sponsor":"Pierre Fabre Medicament","startDate":"2014-04","conditions":"Subject","enrollment":17},{"nctId":"NCT01639014","phase":"PHASE3","title":"Effect of F2695 on Functional Recovery After Ischemic Stroke","status":"COMPLETED","sponsor":"Pierre Fabre Medicament","startDate":"2012-07","conditions":"Ischemic Stroke","enrollment":532},{"nctId":"NCT01254305","phase":"PHASE2","title":"Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Adults With Fatigue Associated With Major Depressive Disorder","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2011-04","conditions":"Major Depressive Disorder","enrollment":262},{"nctId":"NCT01034462","phase":"PHASE3","title":"Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2009-12","conditions":"Major Depressive Disorder","enrollment":442},{"nctId":"NCT00969709","phase":"PHASE3","title":"Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2009-09","conditions":"Major Depressive Disorder","enrollment":724},{"nctId":"NCT00969150","phase":"PHASE3","title":"Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2009-09","conditions":"Major Depressive Disorder","enrollment":362},{"nctId":"NCT01034267","phase":"PHASE3","title":"Safety Study of F2695 SR in Major Depressive Disorder","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2009-12","conditions":"Major Depressive Disorder","enrollment":828}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"F2695","genericName":"F2695","companyName":"Pierre Fabre Medicament","companyId":"pierre-fabre-medicament","modality":"Small molecule","firstApprovalDate":"","aiSummary":"F2695 is a selective inhibitor of fibroblast growth factor receptor (FGFR) signaling that blocks aberrant growth signals in cancer cells. Used for Advanced or metastatic solid tumors with FGFR alterations.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}